Prostate Neuroendocrine Neoplasm
NCI Definition: A neoplasm with neuroendocrine differentiation that arises from the prostate gland. This category includes carcinoid tumors and small cell carcinomas. 
Prostate neuroendocrine neoplasms most frequently harbor alterations in TP53, RB1, TMPRSS2, PTEN, and ERG .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and TP53 Loss are the most common alterations in prostate neuroendocrine neoplasm .
There is 1 clinical trial for prostate neuroendocrine neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains prostate neuroendocrine neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
Avelumab is the most common intervention in prostate neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.